Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. 8 ways 3D printing is making surgery remarkable
3D printing is already making a difference in healthcare: It enables models of organs to train surgeons and educate patients –and improve surgery outcomes.
Doctors previously had to examine actual organs with their hands to get a feel for what they need to do surgically. Now, MRIs and 3D printers eliminate the need to put on gloves and get messy. And surgeons can feel more prepared going into a procedure than they did before. Read more
4. Inovio prices $75m public offering
Inovio Pharmaceuticals said today that it priced its underwritten public offering of 12.5 million shares of common stock at $6.00 apiece. The offering is expected to bring in nearly $75 million for the Plymouth Meeting, Penn.-based company.
The offering, which is expected to close on July 25, includes a 30-day option for underwriters to buy up to 1,875,000 additional shares of common stock. Read more
3. Apollo Endosurgery prices $31m offering
Apollo Endosurgery today priced an upcoming public offering, looking to raise approximately $31 million.
In the offering, Austin, Texas-based Apollo Endosurgery said it will offer 5.7 million shares of its common stock at $5.50 per share, before underwriting discounts and commissions. The round also includes a 45-day underwriters option for an additional 853,363 shares of common stock. Read more
2. Report: China’s Symbow Medical raises $17m
China’s Symbow Medical reportedly raised $17 million (¥120 million) for the MR-safe surgical navigation platform it’s developing.
Huayi Capital led the investment in the Beijing based company, joined by the Chinese government’s National Emerging Industry Guidance Fund, Shandong Buchang Pharmaceuticals Co. and Sangel Capital, the China Money Network reported, citing a Symbow press release. Read more
1. Abbott’s Q2 sales, earnings top forecasts
Abbott beat expectations today with its second-quarter earnings despite a -84% bottom-line slide.
The Chicago-area healthcare giant posted profits of $283 million, or 16¢ per share, on sales of $6.64 billion for the three months ended June 30, for sales growth of 24.5% compared with Q2 2016. Read more